USD10
ACET Shares
About Adicet BioAdicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
USD10
ACET Shares
About Adicet BioAdicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Stats
TRADING WINDOW
Closed
OPENS AT
Jul 31 at 1:30 PM GMT+0
MARKET CAP
$85.16M
OPEN PRICE
$8.97
LOW (1Y)
$6.01
HIGH (1Y)
$17.44
LOW (24H)
$8.55
HIGH (24H)
$9.21
VOLUME (24H)
$123.29K
102.92%
Price history
Time | Price | Change |
|---|---|---|
Today | $8.97 | |
1 Day | $9.40 | |
1 Week | $7.98 | |
1 Month | $8.75 | |
1 Year | Not enough data | Not enough data |
Past performance is not a reliable indicator of future results.
Discover more
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.